Comprehensive sequencing is now an essential checkpoint at every stage in drug development — discover how Oxford Nanopore sequencing can support the development of your cell, gene, and RNA therapy drug modalities. In this Guide, you will learn: How nanopore sequencing enables whole plasmid characterisation, delivering complete confidence in your… Read More
Discover sequencing solutions that can be applied from biomarker discovery through to final product quality control (QC) testing, consolidating multiple legacy assays with one platform — and enabling faster, more confident decision-making. In this new getting started Guide from Oxford Nanopore Technologies, you will: Find out how Oxford Nanopore… Read More
Discover sequencing solutions that can be applied from biomarker discovery through to final product quality control (QC) testing, consolidating multiple legacy assays with one platform — and enabling faster, more confident decision-making. In this new getting started guide, you will: Find out how Oxford Nanopore sequencing delivers the multiomic insight… Read More
Ensuring the integrity of adeno-associated virus (AAV) vectors is critical for gene therapy success, yet traditional methods can miss key structural elements. Download this new Workflow from Oxford Nanopore Technologies to discover how nanopore sequencing enables comprehensive characterisation of AAV genomes — including inverted terminal repeats (ITRs), transgenes, and… Read More
Ensuring the integrity of adeno-associated virus (AAV) vectors is critical for gene therapy success, yet traditional methods can miss key structural elements. Discover how nanopore sequencing enables comprehensive characterisation of AAV genomes — including inverted terminal repeats (ITRs), transgenes, and promoters — all in a single workflow. Download this workflow… Read More
As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More
As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More
As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More
As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More
As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus for an expert-led webinar, hosted by DDW, showcasing new and improved genomics solutions… Read More
In this sponsored DDW Sitting Down With podcast we speak to experts from Lonza and Oxford Nanopore about their collaboration to bring direct mRNA sequencing (including N1-Methyl-pseudouridine) to a regulated environment and establish the new gold standard in sequencing technology. We discuss how nanopore sequencing will… Read More
A new sponsored DDW Sitting Down With podcast is now available. In this podcast, Megan Thomas speaks to experts from Lonza and Oxford Nanopore about their collaboration to bring direct mRNA sequencing (including N1-Methyl-pseudouridine) to a regulated environment and establish the new gold standard in sequencing technology. Read More
Oxford Nanopore Technologies has joined the PROGRESS study to support improved outcomes for childhood leukaemias in Ghana. The consortium so far includes Yemaachi Biotech, Pediatric Oncology Units at Korle Bu Teaching Hospital, Komfo Anokye Teaching Hospital and Greater Accra Regional Hospital, and institutions like Newcastle University,… Read More
Download this new brochure ‘Multiomic nanopore sequencing solutions: Revolutionising human disease research‘ to maximise the data generated from your valuable research samples. Understanding the mechanisms of disease requires complex data ranging from genomic data through to transcriptomics, epigenetics and proteomics. Legacy multiomic approaches require multiple platforms… Read More
Understanding the mechanisms of disease requires complex data ranging from genomic data through to transcriptomics, epigenetics and proteomics. Legacy multiomic approaches require multiple platforms and complex processes, which are incompatible with disease research that utilises scarce tissue samples. Download the brochure to learn how multiomic nanopore sequencing can… Read More
